(Erstwhile UTI Pharma & Healthcare Fund) The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors. UTI Healthcare Fund is a Equity - Sectoral fund launched on 28 Jun 99. It is a fund with High risk and has given a Below is the key information for UTI Healthcare Fund Returns up to 1 year are on Historical performance (Yearly) on absolute basis UTI Healthcare Fund - G
Scheme Objective
CAGR return of 14.5% since its launch. Ranked 40 in Sectoral category. Return for 2025 was -3.1% , 2024 was 42.9% and 2023 was 38.2% . NAV as on 13 Feb 26 ₹279.316 ↓ -4.09 (-1.44 %) Net Assets (AUM) as on 31 Dec 2025 ₹1,102 Cr. Launch Date 28 Jun 1999 Category Equity - Sectoral Rating ☆ Type Open Ended Fund Risk High AMC UTI Asset Management Company Ltd Alpha Ratio -0.86 Expense Ratio 2.26 % Sharpe Ratio -0.48 Information Ratio -0.16 Benchmark Not Available Min Investment ₹5,000 Min SIP Investment ₹500 Exit Load 0-1 Years (1%),1 Years and above(NIL) NAV Price Chart
Returns
Annual Compounded Returns
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 13 Feb 26 Duration Returns 1 Month -0.6% 3 Month -3.5% 6 Month -5.3% 1 Year 5.9% 3 Year 24% 5 Year 14.6% 10 Year 15 Year Since launch 14.5% Historical Annual Returns
Year Returns 2024 -3.1% 2023 42.9% 2022 38.2% 2021 -12.3% 2020 19.1% 2019 67.4% 2018 1.2% 2017 -7.5% 2016 6.2% Growth of 10k Over Years
Date Value 31 Jan 21 ₹10,000 31 Jan 22 ₹11,598 31 Jan 23 ₹10,696 31 Jan 24 ₹15,929 31 Jan 25 ₹19,924 31 Jan 26 ₹20,029 Asset Allocation
Asset Class Value Cash 0.6% Equity 99.4% Sector Allocation
Sector Value Health Care 98.42% Basic Materials 0.98% Top Securities Holdings / Portfolio
Holdings/Securities
Name Global Industry Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 06 | SUNPHARMADrug Manufacturers - Specialty & Generic 9% ₹103 Cr 600,000 Ajanta Pharma Ltd (Healthcare)
Equity, Since 31 Jul 17 | 532331Drug Manufacturers - Specialty & Generic 7% ₹79 Cr 285,000 Lupin Ltd (Healthcare)
Equity, Since 28 Feb 25 | 500257Drug Manufacturers - Specialty & Generic 6% ₹62 Cr 294,991
↓ -24,579 Glenmark Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Mar 24 | 532296Drug Manufacturers - Specialty & Generic 4% ₹45 Cr 220,000
↓ -15,028 Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLANDDrug Manufacturers - Specialty & Generic 4% ₹40 Cr 230,000
↑ 8,838 Procter & Gamble Health Ltd (Healthcare)
Equity, Since 31 Dec 20 | PGHLDrug Manufacturers - Specialty & Generic 3% ₹38 Cr 66,803
↓ -211 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 28 Feb 18 | DRREDDYDrug Manufacturers - Specialty & Generic 3% ₹38 Cr 299,461
↓ -35,539 Cipla Ltd (Healthcare)
Equity, Since 31 Jan 03 | 500087Drug Manufacturers - Specialty & Generic 3% ₹38 Cr 250,000 Alkem Laboratories Ltd (Healthcare)
Equity, Since 31 May 21 | ALKEMDrug Manufacturers - Specialty & Generic 3% ₹37 Cr 68,000 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Apr 21 | APOLLOHOSPMedical Care Facilities 3% ₹37 Cr 53,000
Talk to our investment specialistFund Managers
Name Since Tenure Kamal Gada 2 May 22 3.67 Yr. Custodians
Company Address Axis Bank Ltd null Deutsche Bank AG MUMBAI Deitsche bank,Kodak House Stock Holding Corporation of India Mittal Court, ‘B’ Wing,,Nariman Point Registrar & Transfer Agent
KFin Technologies Ltd Address 138 -Suyesh Solitaire, Nr. Podar International School,Kudasan, Gandhinagar, Gujarat FAX N.A Email N.A Administrator Companies
Company Address UTI Asset Management Co Ltd PMS Division, UTI - Tower, “Gn” Block, Bandra Kurla Complex, Mumbai- 400051 Auditors
Company Address S. R. BATLIBOI & Co Express Tower, 6th Floor,Nariman Point,Mumbai All Plan & Options
Fund and Plan NAV 6 Month 1 Year 3 Year 5 Year UTI Healthcare Fund
Growth ₹279.316
↓ -4.09 -5.34 % 5.91 % 23.95 % 14.59 % UTI Healthcare Fund
Normal Dividend, Payout ₹215.873
↓ -3.16 -5.34 % 5.91 % 23.95 % 14.59 % UTI Healthcare Fund
Normal Dividend, Reinvestment ₹215.873
↓ -3.16 -5.34 % 5.91 % 23.95 % 14.59 % Data as on 13 Feb 26